Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10381 |
AS2717638
|
Others | Others |
AS2717638 是一种具有口服生物活性的,选择性的溶血磷脂酸受体5 (LPA5) 的拮抗剂,其对 hLPA4 的 IC50值为38 nM。AS2717638 还能显著改善 PGE2、PGF2α以及 AMPA 诱导的异位疼痛。 | |||
T4359 |
VAS2870
|
NADPH | Metabolism |
VAS2870 是一种NADPH 氧化酶抑制剂。 | |||
T8378 |
AS2863619
|
CDK; STAT | Cell Cycle/Checkpoint; JAK/STAT signaling; Stem Cells |
AS2863619 是一种口服的细胞周期蛋白依赖性激酶 8 和CDK19抑制剂,抑制CDK8/19可增强STAT5的激活,从而激活 Foxp3 基因。它可将抗原特异性效应子/记忆 T 细胞转换为 Foxp3+调节性 T 细胞,以研究各种免疫疾病。 | |||
T14328 |
AS2521780
|
PKC | Chromatin/Epigenetic; Cytoskeletal Signaling |
AS2521780 is an inhibitor of PKCθ (IC50: 0.48 nM). | |||
T81039 |
TAS2R14 agonist-2
|
||
TAS2R14 agonist-2 (compound 28.1) 作为选择性TAS2R14抑制剂,其EC50为72 nM。 | |||
T81040 |
TAS2R14 agonist-1
|
||
TAS2R14 agonist为一种TAS2R14受体的部分激活分子,其EC50值确定为116.6±23.6 nM。 | |||
T70345 |
JAS239
|
||
JAS239 is a novel carbocyanine dye that binds and competitively inhibits choline kinase (ChoK) intracellularly. JAS239 attenuated choline phosphorylation and viability in a panel of human breast cancer cell lines. Antibody blockade prevented cellular retention of JAS239 indicating direct interaction with ChoKα independent of the choline transporters and catabolic choline pathways. In mice bearing orthotopic MCF7 breast xenografts, optical imaging with JAS239 distinguished tumors overexpressing C... | |||
T70373 |
AS2575959
|
||
AS2575959 is a novel GPR40 agonist, exhibiting glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion. | |||
T26664 |
AS2553627
AS 2553627,AS-2553627 |
||
AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts. | |||
T69912 |
AS2541019
|
||
AS2541019 is a selective Phosphatidylinositol-3-kinase p110δ (PI3Kδ) inhibitor. | |||
T10382 |
AS2863619 free base
|
CDK | Cell Cycle/Checkpoint |
AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells. It is a potent, orally active CDK8 and CDK19 inhibitor (IC50s: 0.61 nM and 4.28 nM). STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene. |